Study Of Investigational Drug To Treat Cocaine And Methamphetamine Addiction

Armen Hareyan's picture
Advertisement

Catalyst Pharmaceutical Partners announced positive initial, top-line results from a bioequivalence study demonstrating that CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable and bioequivalent to Sabril Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis.

These data potentially provide a basis for linking CPP-109 to the extensive body of published pre-clinical and clinical literature on Sabril.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement

Comments

I would like to know if this is open to public studies. i know people who need these type of pills and was wondering if we could get them?